TrialJournal of cancer research and clinical oncology2019

First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression.

Martin Schuler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.